Loading
LOADING
A synthetic heptapeptide derived from the immunomodulatory tuftsin, with documented effects on anxiety, immunity, and enkephalin metabolism.
Selank is a synthetic heptapeptide developed at the same Russian research institute as Semax. Its sequence — Thr-Lys-Pro-Arg-Pro-Gly-Pro — represents the tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended with a tripeptide tail (Pro-Gly-Pro) for enzymatic stability.
Tuftsin is a naturally occurring tetrapeptide derived from the Fc region of immunoglobulin G (IgG). It was identified in the 1970s as an immunomodulator with effects on macrophage function, phagocytosis, and broader immune signaling. Tuftsin itself has a very short biological half-life, which limited its research utility.
The Selank design — adding the PGP stabilizing tail — produces a tuftsin-derived peptide stable enough for practical research while retaining the parent peptide's biological activity. This design strategy parallels the approach used for Semax, where the same PGP extension was used to stabilize the ACTH fragment.
The most distinctive feature of Selank research is its anxiolytic (anti-anxiety) activity. This is unusual for a peptide derived from an immunological precursor and reflects the broader theme of melanocortin-family peptides showing CNS effects beyond their classical signaling roles.
A series of Russian studies has documented Selank's anxiolytic effects across animal and human research:
Animal models. A 2008 study examining the efficacy and possible mechanisms of Selank documented anxiolytic effects across multiple anxiety-relevant behavioral paradigms in rodents.
Direct comparison with benzodiazepines. A 2014 study in Zhurnal Nevrologii i Psikhiatrii directly compared the anxiolytic effect and tolerability of Selank with phenazepam (a benzodiazepine), documenting comparable anxiolytic activity but a distinct side effect profile. Critically, Selank did not produce the sedation, cognitive impairment, or dependence potential associated with benzodiazepines.
Combination effects. A 2017 study in Behavioural Neurology documented that Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress models, suggesting potential value in combination protocols.
A 2001 study in Bulletin of Experimental Biology and Medicine documented one of Selank's primary biochemical effects: inhibition of enkephalin-degrading enzymes.
Enkephalins are endogenous opioid peptides involved in pain modulation, mood regulation, and stress responses. They are normally rapidly degraded by enzymes including enkephalinase and aminopeptidases. By inhibiting these degrading enzymes, Selank effectively prolongs the action of endogenous enkephalins, producing analgesic and anxiolytic effects through enhanced endogenous opioid signaling.
A 2006 follow-up study examined the involvement of opioid pathways more directly. Researchers documented that the anxiolytic effect of Selank was blocked by naloxone (an opioid receptor antagonist), confirming opioid receptor involvement in Selank's mechanism.
This mechanism is distinctive among anxiolytic compounds. Most benzodiazepines act through GABA-A receptor potentiation. SSRIs act through serotonin reuptake inhibition. Selank's enkephalin-enhancing mechanism is a third pathway that does not overlap with either, potentially explaining the favorable side-effect profile relative to benzodiazepines.
Beyond enkephalin metabolism, Selank has documented effects on broader monoamine systems:
A 2009 study in Eksperimental'naia i Klinicheskaia Farmakologiia compared the effects of Selank and tuftsin on serotonin metabolism, documenting modulation of serotonergic activity that may contribute to the anxiolytic and mood-related effects.
The interactions with dopaminergic and serotonergic systems are reminiscent of Semax's effects, suggesting that both Russian heptapeptides may engage shared monoamine pathways despite different receptor entry points.
Given Selank's origin as a tuftsin analog, immunological effects are an expected research direction. The published literature documents:
Effects on inflammatory gene expression. A 2011 study in Genetika examined changes in expression of genes for chemokines, cytokines, and their receptors under Selank administration, documenting modulation of inflammatory signaling.
Tuftsin-like immune modulation. A 2014 study in Molecular Immunology examined the temporal dynamics of inflammation-related gene expression under tuftsin and Selank administration, documenting overlapping but distinct effects.
These immunological effects are biologically interesting but less well-characterized than the anxiolytic and analgesic effects in terms of clinical relevance.
Like Semax, Selank has been studied predominantly via intranasal administration:
Intranasal route is the standard administration form. A 2016 study in Eksperimental'naia i Klinicheskaia Farmakologiia compared pharmacological effects of Selank after intranasal administration, providing reference pharmacokinetic and pharmacodynamic data.
Half-life is short — Selank's bioactive form is rapidly metabolized by serum peptidases. The PGP stabilization extends activity meaningfully relative to tuftsin but does not produce extended-duration administration profiles.
Dose response has been characterized in Russian clinical research, with typical research doses producing measurable anxiolytic effects within hours of administration.
Russian clinical research has examined Selank in several anxiety-related applications:
Most published clinical research is in Russian journals with methodology and reporting standards that differ from international clinical trial norms. Independent replication by groups outside the Russian research community is limited.
A 2019 study in Bulletin of Experimental Biology and Medicine examined Selank's protective effects against ethanol-induced memory impairment, demonstrating cognitive protective effects in a model relevant to the broader anxiety-cognitive overlap.
Selank's research profile makes it interesting for several reasons:
Distinct mechanism from major anxiolytic classes. Selank's enkephalin-enhancing mechanism does not overlap with benzodiazepines, SSRIs, or other established anxiolytics. This makes it mechanistically novel even if clinical applications remain limited.
Favorable side effect profile. Russian clinical data and animal model studies consistently document the absence of sedation, cognitive impairment, dependence, or withdrawal — features that make benzodiazepines problematic for extended use.
Bidirectional immune effects. The tuftsin-derived immunomodulatory properties may have research applications beyond anxiety, though these are less well-characterized.
Limited Western validation. As with Semax, the absence of independent Western trials limits the broader applicability of Russian clinical findings to international research contexts.
Despite the substantial Russian research base, Selank has not advanced through Western clinical development. The reasons reflect a combination of regulatory, commercial, and methodological factors rather than negative efficacy findings. The compound represents an interesting case study in how research peptides can establish substantial clinical use in one research tradition while remaining largely outside another.
For research interpretation, Selank's documented effects on enkephalin metabolism, opioid receptor signaling, and anxiety-related behaviors are reproducibly supported by the available literature. The translation of these effects to clinical applications outside the Russian research context remains an open question.
NoteThis article is intended for informational and educational purposes only. It does not constitute medical advice.
Still have questions?
ASK AXIOM ABOUT THIS TOPIC →